Company profile for Adamas Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Adamas turns this purpose into reality by combining expertise in development and experience in commercialization with a passion for improving lives. Our vision is to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company with deep expertise in development and commercialization of neurological therapies. In 2018, Adamas successfully...
Adamas turns this purpose into reality by combining expertise in development and experience in commercialization with a passion for improving lives. Our vision is to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company with deep expertise in development and commercialization of neurological therapies. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1900 Powell St, Ste 1000, Emeryville, CA 94608
Telephone
Telephone
510-450-3500
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2021/11/24/2340624/19871/en/Supernus-Pharmaceuticals-Completes-Acquisition-of-Adamas-Pharmaceuticals.html

GLOBENEWSWIRE
24 Nov 2021
Supernus strikes $400M+ Adamas buyout, tempering patent cliff
Supernus strikes $400M+ Adamas buyout, tempering patent cliff

12 Oct 2021

// E. Sagonowsky FIERCEPHARMA

https://www.fiercepharma.com/pharma/supernus-strikes-400m-adamas-buyout-as-its-top-drug-heads-toward-patent-cliff

E. Sagonowsky FIERCEPHARMA
12 Oct 2021
Supernus and Pacira swoop while their targets are down
Supernus and Pacira swoop while their targets are down

11 Oct 2021

// Madeleine Armstrong EVALUATE

https://www.evaluate.com/vantage/articles/news/deals/supernus-and-pacira-swoop-while-their-targets-are-down

Madeleine Armstrong EVALUATE
11 Oct 2021

https://www.businesswire.com/news/home/20210910005553/en

BUSINESSWIRE
10 Sep 2021

https://www.businesswire.com/news/home/20210830005541/en

BUSINESSWIRE
30 Aug 2021

https://www.businesswire.com/news/home/20210813005399/en

BUSINESSWIRE
13 Aug 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty